1. Home
  2. WBX vs ENGN Comparison

WBX vs ENGN Comparison

Compare WBX & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wallbox N.V.

WBX

Wallbox N.V.

HOLD

Current Price

$2.94

Market Cap

65.2M

ML Signal

HOLD

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

HOLD

Current Price

$2.05

Market Cap

117.2M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
WBX
ENGN
Founded
2015
1999
Country
Spain
Canada
Employees
N/A
N/A
Industry
Industrial Specialties
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
65.2M
117.2M
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
WBX
ENGN
Price
$2.94
$2.05
Analyst Decision
Buy
Buy
Analyst Count
4
6
Target Price
$4.75
$21.08
AVG Volume (30 Days)
11.0K
654.6K
Earning Date
05-06-2026
06-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
56.85
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$18.10
N/A
Revenue Next Year
$94.11
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.30
$1.40
52 Week High
$7.83
$12.25

Technical Indicators

Market Signals
Indicator
WBX
ENGN
Relative Strength Index (RSI) 45.26 62.65
Support Level $3.00 $1.67
Resistance Level $3.19 $7.92
Average True Range (ATR) 0.19 0.07
MACD 0.01 0.02
Stochastic Oscillator 16.11 94.23

Price Performance

Historical Comparison
WBX
ENGN

About WBX Wallbox N.V.

Wallbox NV is a smart electric vehicle charging and energy management company. It creates a smart charging system combining technology design that manages the communication between the user, vehicle, grid, building, and charger. The company designs, manufactures, and distributes faster, simpler EV charging solutions for residential, business, and public use. Its smart charging product portfolio includes Level 2 alternating current chargers for home and business applications and direct current fast chargers for public applications. The company has three reportable operating segments: Europe, the Middle East and Asia (EMEA), its key revenue-generating segment, North America, and Asia-Pacific.

About ENGN enGene Holdings Inc.

enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

Share on Social Networks: